SLC16A4: A Potential Drug Target and Biomarker for Monocarboxylate Transporter 5 (ISO Form 3)

Target Name: SLC16A4

NCBI ID: G9122

SLC16A4

SLC16A4: A Potential Drug Target and Biomarker for Monocarboxylate Transporter 5 (ISO Form 3)

Monocarboxylate transporter 5 (MCT5) is a gene that encodes a protein known as MCT5. MCT5 is a transmembrane protein that is primarily located in the endoplasmic reticulum (ER) and is responsible for transporting monocarboxylates across the ER membrane. MCT5 is a critical protein that plays a vital role in the regulation of intracellular monocarboxylate levels, which are essential for various cellular processes. The deregulation of monocarboxylate levels has been implicated in numerous diseases, including obesity, diabetes, and neurodegenerative disorders.

SLC16A4 is a gene that encodes a protein known as SLC16A4. SLC16A4 is a member of the solute carrier family 16 (SLC16) and is responsible for transporting monocarboxylates across the ER membrane. SLC16A4 is a key regulator of monocarboxylate transport and has been implicated in the development and progression of various diseases.

The SLC16A4 gene has been extensively studied for its potential as a drug target or biomarker. Several studies have suggested that SLC16A4 may be a drug target for obesity, diabetes, and other diseases due to its involvement in monocarboxylate transport. Additionally, SLC16A4 has been shown to be a potential biomarker for monitoring the efficacy of certain treatments in these diseases.

SLC16A4 and Monocarboxylate Transport

SLC16A4 is a member of the SLC16 family, which includes several other proteins that are involved in the transport of various types of molecules across cell membranes. The SLC16 family is characterized by the presence of a transmembrane region, a cytoplasmic region, and an N-terminus.

SLC16A4 is responsible for transporting monocarboxylates across the ER membrane. Monocarboxylates are specialized molecules that are composed of a carbonate group and an amino acid side chain. They are essential for various cellular processes, including energy metabolism and signaling pathways.

SLC16A4 is a type I transmembrane protein that consists of a 16-amino acid residue. It has a cytoplasmic region that is involved in the formation of a transmembrane interface and is responsible for the stability of the protein. The N-terminus of SLC16A4 is located in the ER and is responsible for its binding to specific receptors, which are essential for its function.

SLC16A4 has been shown to play a critical role in the regulation of monocarboxylate transport in various cellular contexts. For example, studies have shown that SLC16A4 is involved in the transport of carbonyl-containing molecules across the ER membrane, including malonyl-CoA, which is a key substrate for the citric acid cycle.

Drug Targeting and Biomarker

SLC16A4 has been suggested as a potential drug target for various diseases due to its involvement in monocarboxylate transport. Obesity, diabetes, and other diseases are characterized by the dysregulation of monocarboxylate levels, which is thought to contribute to the development and progression of these diseases.

SLC16A4 has been shown to be involved in the regulation of monocarboxylate transport in obesity. Several studies have shown that individuals with obesity have lower levels of SLC16A4 than individuals with normal weight. Additionally, studies have shown that inhibiting SLC16A4

Protein Name: Solute Carrier Family 16 Member 4

Functions: Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity)

The "SLC16A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets